Application of tSFTA3 in the prevention and treatment of lung cancer

By using the protein encoded by the SFTA3 gene or its truncated mutant tSFTA3, the sensitivity of lung adenocarcinoma and lung squamous cell carcinoma cells to targeted drugs is enhanced, solving the problem of poor efficacy of existing treatments and achieving improved tumor suppression and therapeutic effects.

CN118178448BActive Publication Date: 2024-11-26NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410297372.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-15
Publication Date
2024-11-26
Estimated Expiration
2044-03-15

AI Technical Summary

Technical Problem

Existing chemotherapy drugs and immunotherapy are not very effective for advanced lung adenocarcinoma and have side effects, so there is a lack of effective treatment options.

Method used

By using the protein encoded by the SFTA3 gene or its truncated mutant tSFTA3, expressed via a lentiviral vector, the sensitivity of lung adenocarcinoma and lung squamous cell carcinoma cells to targeted drugs is enhanced, cell proliferation is inhibited, and tumor growth is suppressed.

Benefits of technology

It significantly inhibits the proliferation of lung adenocarcinoma and lung squamous cell carcinoma cells, enhances sensitivity to targeted drugs, improves treatment efficacy, and inhibits tumor growth in animal experiments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118178448B_ABST
    Figure CN118178448B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biotechnology, and specifically discloses the use of tSFTA3 in the prevention and treatment of lung cancer. On the one hand, it relates to the use of tSFTA3 in the preparation of drugs for the prevention and treatment of lung adenocarcinoma and / or lung squamous cell carcinoma; on the other hand, it relates to the use of tSFTA3 in the preparation of products that enhance the sensitivity of lung cancer cells to targeted drugs; it also relates to the use of tSFTA3 in combination with at least one of trametinib, dabrafenib, and sotolacib in the preparation of products for the prevention and treatment of lung cancer. In the present invention, the tSFTA3 gene has a protein coding function, and the protein can significantly inhibit the proliferation of lung adenocarcinoma cell lines after expression, enhance the sensitivity of tumor cells to targeted therapeutic drugs, and inhibit the growth of tumors in animal experiments, indicating that the expression vector of tSFTA3 (such as pLVX‑puro‑tSFTA3 used in the present invention) may be used as a new method for inhibiting tumor growth and improving the effect of targeted therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to the use of tSFTA3 in the prevention and treatment of lung cancer. Background Art

[0002] Lung cancer is one of the most common malignant tumors in the world, of which non-small cell lung cancer is the main type, accounting for about 80%; NSCLC mainly includes lung adenocarcinoma and lung squamous cell carcinoma, with lung adenocarcinoma being the most common. Advanced lung adenocarcinoma is prone to metastasize to other organs, including the liver and brain, and is the main cause of death from non-small cell lung cancer.

[0003] Surfactant factor associated 3 (SFTA3) is a long non-coding RNA (lncRNA), which is widely present in animals and plants and plays an important role in regulating gene expression. A large number of studies have confirmed that abnormal expression of lncRNA is closely related to disease. The genome coordinates (GRCh38): 14: 36,473,288-36,519,556 (from NCBI), the gene has 10 transcripts (splicing variants), and its expression is restricted to the lungs (RPKM 71.4).

[0004] Currently, chemotherapy drugs for the clinical treatment of advanced lung adenocarcinoma are ineffective and have serious side effects, and immunotherapy is only effective in a small number of patients, so new treatments are urgently needed. SFTA3 has been proven to be a diagnostic marker for squamous cell carcinoma and adenocarcinoma of the lung (CN104698191B), but the inhibitory effect of SFTA3 on tumors is still unclear, and it is not possible to conduct research on the treatability of lung cancer based on this. Summary of the invention

[0005] In order to solve the above problems, the present invention provides a new use of tSFTA3 in tumor treatment, mainly to supplement and improve the treatment methods for lung cancer and enhance the therapeutic effect of the treatment methods for lung cancer.

[0006] In order to solve the above problems, the present invention adopts the following technical solutions:

[0007] The first aspect involves the use of SFTA3 in the preparation of drugs for the prevention and treatment of lung adenocarcinoma and / or lung squamous cell carcinoma. SFTA3 (surfactant associating 3) is the SFTA3 gene, which can encode the SFTA3 protein. When SFTA3 can encode protein normally, it can effectively inhibit the proliferation of lung adenocarcinoma cells and lung squamous cell carcinoma cells, and enhance the sensitivity of lung adenocarcinoma cells and lung squamous cell carcinoma cells to targeted drugs, thereby improving the effect of targeted drugs. Among them, the targeted drug is at least one of trametinib, dabrafenib, and sotolacib (it can also be other similar drugs).

[0008] The second aspect relates to the use of tSFTA3 (a truncated mutant of SFTA3) in the preparation of a drug for preventing and treating lung adenocarcinoma and / or lung squamous cell carcinoma; wherein the base sequence of the tSFTA3 is shown in SEQ ID NO: 1. The tSFTA3 carried by the truncated mutant of SFTA3 has a protein encoding function, and the encoded protein can be expressed normally. tSFTA3 can effectively inhibit the proliferation of lung adenocarcinoma cells and lung squamous cell carcinoma cells, thereby inhibiting the development of tumors and even achieving the treatment of tumors.

[0009] SEQ ID NO: 1 is specifically:

[0010] ATGAGAGCCGGGTTTTTCTGACTTCCAACTCATTAGGGACCAGGTTCTTTTTCTCAGGATCAGGCACAGAGACTGACTGAATGGCTCCAATTATCAGGATTTGAAAACCCAGTATCAGAATCTACCACTTTGTGCCTGAGG GAGAGGGAAAAGCGGATACCCACCTGTGTCGCTGTTTGCGTGCCAAGTCCAGGAACAGTCCATACAGCCCTGCTGCATCCCACGACGCTGTCACAAAGCAGGAGTTCATCCGAGGCCAAGATGTTAATTATTCATACTGCA.

[0011] In order to facilitate the application of tSFTA3, for this application, some conditions in the application process can be selected arbitrarily. For situations not specifically stated, reference can be made to the prior art:

[0012] One of them is that the upstream added sequence of tSFTA3 is the classic Kozak sequence (GCCACC), and the addition of the Kozak sequence is beneficial to increase the efficiency of protein translation. The Kozak sequence can also be replaced by other equivalent schemes, but all should be considered within the scope of the present invention.

[0013] Second, the downstream added sequence of tSFTA3 is any one of V5 tag, FLAG tag and HIS tag added downstream of tSFTA3, the V5 tag sequence is SEQ ID NO: 2, wherein the last 3 bases TGA are stop codons, and whether or not the stop codon TGA is contained in actual application should be within the scope of the present invention, and the addition of the tag is selected to facilitate the detection of the expression of the peptide segment with an anti-V5 antibody, and of course, other equivalent schemes such as FLAG tag and HIS tag can also be used without further elaboration;

[0014] SEQ ID NO:2 specifically:

[0015] GGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGTGA.

[0016] Thirdly, the tSFTA3 is loaded into a lentiviral expression vector, and the lentiviral vector carrying the truncated mutant tSFTA3 gene can infect tumor cells and express in the cells. Furthermore, the tSFTA3 can be used in the preparation of drugs for preventing and treating lung adenocarcinoma and / or lung squamous cell carcinoma in the form of a truncated mutant expression vector pLVX-puro-tSFTA3, which is obtained by inserting tSFTA3 into the lentiviral expression vector pLVX-Puro as a vector.

[0017] The third aspect involves the use of tSFTA3 in the preparation of products that enhance the sensitivity of lung cancer cells to targeted drugs; wherein the base sequence of the tSFTA3 is as shown in SEQ ID NO: 1; the targeted drug is at least any one of trametinib, dabrafenib, and sotolacib. tSFTA3 enhances the sensitivity of tumor cells to targeted drugs, thereby improving the effect of targeted drugs on tumor cells, and then achieving the improvement of the therapeutic effect of targeted drugs on tumor diseases. Products that enhance the sensitivity of lung cancer cells to targeted drugs are generally auxiliary products for tumor treatment. This auxiliary product does not contain targeted drugs in this application. Here, the main consideration is its gain effect on targeted drugs in the treatment of tumors. Whether it itself has the effect of inhibiting tumors is not considered for the time being. All applications involving tSFTA3 as a gain product should be considered within the scope of the present invention. In addition, in addition to being used for therapeutic purposes, the gain product can also have other uses, such as regulating the effect of targeted drugs through tSFTA3 in some commercial research experiments.

[0018] For this application, some conditions can be selected arbitrarily during the application process. For situations not specifically stated, reference can be made to the prior art:

[0019] In one of them, the lung cancer cells can be lung adenocarcinoma cells or lung squamous cell carcinoma cells. Furthermore, the lung cancer cells are A549 cells or H358 cells.

[0020] Secondly, tSFTA3 can also be loaded by a lentiviral expression vector when used, specifically in the form of pLVX-puro-tSFTA3.

[0021] The fourth aspect relates to the use of tSFTA3 for non-diagnostic therapeutic purposes in vitro to inhibit the proliferation of A549 cells or H358 cells; wherein the base sequence of the tSFTA3 is shown in SEQ ID NO:1.

[0022] In this application, the role of tSFTA3 is more applied in in vitro biological models to regulate cell proliferation.

[0023] The fifth aspect relates to the use of SFTA3 or tSFTA3 in combination with at least one of trametinib, dabrafenib, and sotolacib in the preparation of products for the prevention and treatment of lung cancer; wherein, the base sequence of the tSFTA3 is as shown in SEQ ID NO: 1. When SFTA3 or tSFTA3 is combined with at least one of trametinib, dabrafenib, and sotolacib to form a mixture, as long as any one of SFTA3 and tSFTA3 is used in combination with targeted drugs, it should be regarded as within the scope of the present invention, and the selection of the combined object can be any one of trametinib, dabrafenib, and sotolacib, or any combination of multiple ones. The remaining equivalent schemes other than trametinib, dabrafenib, and sotolacib should also be regarded as equivalent schemes of the present invention. The combined use of SFTA3 or tSFTA3 with targeted drugs produces a synergistic gain effect, thereby significantly improving the therapeutic effect on tumors. Among them, lung cancer can specifically be lung adenocarcinoma or lung squamous cell carcinoma.

[0024] The beneficial effects of the present invention are:

[0025] The tSFTA3 gene has a protein coding function. After expression, the protein can significantly inhibit the proliferation of lung adenocarcinoma cell lines, enhance the sensitivity of tumor cells to targeted therapeutic drugs, and inhibit tumor growth in animal experiments. This shows that the expression vector of tSFTA3 (such as the pLVX-puro-tSFTA3 used in the present invention) may be used as a new method to inhibit tumor growth and improve the effect of targeted therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 :The expression of SFTA3 in BEAS-2B, H358 and A549 cell lines was detected by fluorescence quantitative PCR;

[0027] Figure 2 :Schematic diagram of the structure of pLVX-Puro empty cloning vector;

[0028] Figure 3 : Schematic diagram of the structure of the full-length SFTA3 gene expression vector pLVX-Puro-SFTA3;

[0029] Figure 4 : Schematic diagram of the structure of the truncated mutant SFTA3 (tSFTA3) gene;

[0030] Figure 5 : Schematic diagram of the structure of the truncated mutant SFTA3 (tSFTA3) gene expression vector pLVX-puro-tSFTA3;

[0031] Figure 6: qPCR detection of the expression levels of SFTA3 or tSFTA3 in H358 and A549 cells after transfection;

[0032] Figure 7 : The expression of tSFTA3 protein was detected using anti-V5 antibody;

[0033] Figure 8 : CCK8 assay was used to detect the proliferation of H358 cells;

[0034] Fig. 9 : CCK8 method was used to detect the survival rate of cells after AMG510 treatment;

[0035] Fig.10 :H358 tumor cell subcutaneous transplantation tumor experiment in mice;

[0036] Fig.11 : CCK8 assay was used to detect the proliferation of A549 cells;

[0037] Fig.12 :CCK8 assay was used to detect the survival rate of cells after treatment with Trametinib;

[0038] Fig.13 :Subcutaneous transplantation experiment of A549 tumor cells in mice. DETAILED DESCRIPTION

[0039] The present invention is described in detail below in conjunction with specific research projects.

[0040] Embodiment 1: Design and preparation of tSFTA3

[0041] (1) Analyze the expression of SFTA3 in normal bronchial epithelial cell line (BEAS-2B) and lung adenocarcinoma cells H358 and A549. Total RNA of BEAS-2B, H358 and A549 cells was extracted using Trizol reagent according to conventional methods, and the expression of SFTA3 was detected by fluorescence quantitative PCR (qPCR). The results showed that compared with BEAS-2B cells, the expression of SFTA3 in H358 and A549 cells was significantly decreased ( Figure 1 ). The primer sequences for detecting SFTA3 expression were: upstream primer 5'-AGCCGGGTTTTCTGACTTCC-3'; downstream primer: 5'-CGCTTTTCCCTCTCCCTCAG-3';

[0042] Note: The full length of SFTA3 gene is 1531bp, and the sequence is as follows, where the underlined sequence is a 285bp protein coding region, and the expected coding product is a peptide containing 94 amino acids. The double underlined part is the qPCR primer binding region, and the length of the qPCR product is 150bp.

[0043] GGGAGCTGTGGGCAGGAGAGGAAGGAAAGCAGCTCTCTCAGCTAGCGAGGGGGTCAGGGACTGGGCCAAGCTCAGAAGCGGGGAGAAGAGCGAGACAGAGATGCTCTGAGCAGGGGAGACAGGGATCCCGGGCTGCTGCCGCTACCAACAAGGGTACACACTGCGGTCCTCAAGGCCAGGAGGGGGGTGGGGGCAGGGAATGCCTCAGCCAACAGGGCAGCGGCTCGGCCCTGCTGCTGGCCCGGTGGGAAGTAGCCTGGGGCCCCGCGACTGAAATCCGAGCCAGGCCTGGGCAGTCTCCGCTAGAAACGCTCTGGGCGCGCACTCCTGGAGACGCGGAGGCCCGGGCGCTCCAGACCAGTGTCCTTGTAGGAGGCTTCTTCACGAAGCTTAGAGTTTGGCCTTTCATAGGGAAAGACTTGCTCGGGAGCAAGTCTAAGGGATTTTAAGGGATTTTAAATCTTCCTGGGCCAGGGCTAGGGAGCTCTAGTGACAGTGTCTTGGTCTGGAATCCAACTCTCCAATTTTGAGGCCGCAGGGAGGAATTCTGAGACTTTAGAGGCCGCACAGCCTTCAGCGCGCTCACCGCGTCCAGGCGTCAGTGAGGGGCTATCTCGAGGCGCGAGTGCACAAAAGGTAGCGCGAGTCTCTTCTCAGGCGATCCAGATAAGAGGAA ATGAGAGCCGGGTTTTTCTGACTTCCAACTCATTAGGGACCAGGTTCTTTTTCTTCAGGATCAAGGCACAGAGACTGA CTGAATGGCTCCAATTATCAGGATTTGAAAACCCAGTATCAGAATCTACCACTTTGTGCCTGAGGGAGAGGGAAAA GCGGATACCCACCTGTGTCGCTGTTTGCGTGCCAAGTCCAGGAACAGTCCATACAGCCCTGCTGCATCCCACGACG CTGTCACAAAGCAGGAGTTCATCCGAGGCCAAGATGTTAATTATTCATACTGCATGA.

[0044] (2) Construction of the full-length SFTA3 vector pLVX-puro-SFTA3. The lentiviral expression vector pLVX-Puro (empty vector without the target gene, purchased from Clontech, with a full length of 8102 bp, Figure 2 ), the full-length SFTA3 gene was inserted into the SmaI site in the multiple cloning site (MSC) of the vector using conventional molecular cloning methods to obtain the pLVX-Puro-SFTA3 vector ( Figure 3 , total length 9633bp).

[0045] (3) Construction of truncated mutant expression vector pLVX-puro-tSFTA3. Although the SFTA3 gene is considered to be a long non-coding RNA gene, it contains a protein coding sequence, namely Figure 3The 285 bp open reading frame (ORF) in the gene may encode a 94-amino acid peptide and play a biological role. In order to test the function of the ORF product, we constructed an expression vector pLVX-puro-tSFTA3 containing the truncated mutant SFTA3 by gene synthesis. Figure 4 As shown, after removing the original stop codon TGA, the tSFTA3 gene contains a 282bp ORF sequence, and then the classic Kozak sequence GCCACC is added upstream, which may be beneficial to increase the efficiency of protein translation; a V5 tag is added downstream, which provides a means to detect the expression of the peptide using an anti-V5 antibody.

[0046] The V5 tag sequence is: GGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACG TGA The last three bases TGA are the stop codon. The structure of tSFTA3 gene is as follows Figure 4 As shown, the length is 333 bp. Figure 5 Schematic diagram of the structure of the pLVX-puro-tSFTA3 expression vector, which is 8435 bp in length.

[0047] Embodiment 2: tSFTA3 significantly inhibits the proliferation of lung cancer H358 cells and enhances their sensitivity to targeted drugs

[0048] (1) 293T cells were used to package lentivirus, which was then used to infect H358 and A549 cells to obtain H358 and A549 cells that highly expressed SFTA3 or tSFTA3. Control cells were infected with lentivirus containing an empty vector. The specific steps are as follows:

[0049] a) 24 h before plasmid transfection, 2×10 6 293T cells were plated in a 10 cm culture dish.

[0050] b) During transfection, follow the operating procedures of lipofectamine 3000 to mix the expression vector (pLVX-puro-SFTA3, pLVX-puro-tSFTA3 or control pLVX-Puro empty clone), packaging vector psPAX2 and PMD2.g with Opti-MEM culture medium in a ratio of 10:5:1.5, let it stand for 15 minutes, and then evenly add it to the 293T cell culture dish.

[0051] c) 6 h after plasmid transfection, the culture medium was replaced with new DMEM complete medium containing 10% fetal bovine serum.

[0052] d) After 48 h of culture, the supernatant of the culture medium containing the lentiviral particles was collected and stored in a -80°C refrigerator, and replaced with new DMEM complete medium; after 72 h of culture, the supernatant of the culture medium containing the lentiviral particles was collected again and stored in a -80°C refrigerator.

[0053] e) Cultivate H358 and A549 cells until the logarithmic growth phase, and thaw the lentivirus solution stored in a -80°C refrigerator on ice. Take an appropriate amount of the lentivirus solution and add 8 mg / ml polybrene to prepare the lentivirus infection solution, and add it to the target H358 and A549 cells.

[0054] f) 24 h after infection, remove the lentiviral infection medium and add new complete culture medium for culture.

[0055] g) 72 h after infection, cells were screened with puromycin (2 μg / ml) for 3-5 days to obtain puromycin-resistant cells, i.e., stable infection strains.

[0056] h) Detect the expression of SFTA3 or tSFTA3 by qPCR to verify the high expression of the target gene in the cell line. Figure 6 As shown, the levels of target gene (SFTA3 or tSFTA3) expressed in H358 and A549 cells stably infected with pLVX-puro-SFTA3 or pLVX-puro-tSFTA3 lentivirus were significantly higher than those in the control group.

[0057] i) Using anti-V5 antibody, Western blot was used to detect H358 and A549 cells infected with pLVX-puro-tSFTA3 lentivirus, and a clear band was found, the size of which was in line with the expected value of about 12 kDa ( Figure 7 ), indicating that the protein encoded by the tSFTA3 gene can be expressed smoothly.

[0058] (2) Inoculate 100 μl of transfected H358 cells in a 96-well cell culture plate, 2×10 3 cells / well, and the OD450 value was detected by CCK8 method after 24-72 hours to represent the degree of cell proliferation. The CCK8 kit was purchased from Abmole (Catalog No.: M4839), and the operation was strictly in accordance with the instructions. The test results showed that compared with the control group, transfection of full-length SFTA3 did not significantly inhibit the proliferation of H358 cells, while the proliferation rate of H358 cells transfected with tSFTA3 was significantly slowed down ( Figure 8 ).

[0059] (3) KRAS G12C Targeted agent AMG510 for KRAS G12C Mutated tumor cells have a specific killing effect. H358 cells carry KRAS G12CMutation, so it can be used to test the sensitivity of tumor cells to AMG510. 2×10 3 After transfection, H358 cells were treated with low (1ng / ml), medium (10ng / ml), and high (100ng / ml) concentrations of AMG510 for 72 hours. The cell survival rate was detected by CCK8 method (compared with cells without drug addition). The results showed that the sensitivity of cells transfected with tSFTA3 to AMG510 was significantly increased (manifested by a significant decrease in cell survival rate), and the sensitivity of cells transfected with full-length SFTA3 to AMG510 also tended to increase in the medium and high concentration groups ( Fig. 9 ).

[0060] (4) Mouse subcutaneous transplant tumor experiment: 3×10 control H358 cells in the logarithmic growth phase or H358 cells stably infected with pLVX-puro-SFTA3 or pLVX-puro-tSFTA3 lentivirus were collected. 5 , fully suspended in 200ul PBS phosphate buffer solution, inoculated subcutaneously into 6-week-old NOD immunodeficient mice, dynamically measured tumor size, tumor weight, and recorded survival time. The calculation of tumor volume is: 0.52×length×width×width (mm3). Fig.10 As shown, the growth of H358 tumors transfected with pLVX-puro-tSFTA3 was slower than that of control tumors (p<0.01), while there was no significant difference in the growth of tumors transfected with pLVX-puro-SFTA3 and control tumors (NS), indicating that pLVX-puro-tSFTA3 has an inhibitory effect on tumor growth.

[0061] Embodiment three: tSFTA3 inhibits the proliferation of lung cancer A549 cells and enhances their sensitivity to targeted drugs

[0062] (1) The method of overexpressing full-length SFTA3 or tSFTA3 in A549 cells and the detection methods of qPCR and WB were the same as those in Examples 1 and 2.

[0063] (2) Inoculate 100 μl of transfected A549 cells in a 96-well cell culture plate, 2×10 3 cells / well, and OD450 was measured by CCK8 method after 24-72 hours to represent the degree of cell proliferation, and the method was the same as in Example 2. The test results showed that compared with the control group, transfection with full-length SFTA3 did not significantly inhibit the proliferation of A549 cells, but the proliferation rate of H358 cells transfected with tSFTA3 was significantly slowed down ( Fig.11 ).

[0064] (3) A549 cells carrying KRAS G12SMutation, which leads to excessive activation of the MAPK signaling pathway (KRAS / RAF / MEK / ERK) in tumor cells, so the MEK inhibitor trametinib has a certain killing effect on A549 cells. 2×10 3 After transfection, A549 cells were treated with low (0.2 ng / ml), medium (1 ng / ml), and high (5 ng / ml) concentrations of Trametinib for 72 hours. The cell survival rate was detected by CCK8 assay (compared with cells without drug addition). The results showed that cells transfected with tSFTA3 were significantly more sensitive to Trametinib (as shown by a significant decrease in cell survival rate), while cells transfected with full-length SFTA3 had no significant change in sensitivity to Trametinib ( Fig.12 ).

[0065] (4) Mouse subcutaneous transplant tumor experiment: 3×10 control A549 cells in the logarithmic growth phase or A549 cells stably infected with pLVX-puro-SFTA3 or pLVX-puro-tSFTA3 lentivirus were collected. 5 , fully suspended in 200ul PBS phosphate buffer solution, inoculated subcutaneously into 6-week-old NOD immunodeficient mice, dynamically measured tumor size, tumor weight, and recorded survival time. The calculation of tumor volume is: 0.52×length×width×width (mm3). Fig.13 As shown, the growth of A549 tumors transfected with pLVX-puro-tSFTA3 was slower than that of control tumors (p<0.05), while there was no significant difference in the growth of tumors transfected with pLVX-puro-SFTA3 and control tumors (NS). This result is consistent with the results of the H358 cell transplantation experiment, which fully demonstrates that pLVX-puro-tSFTA3 has an inhibitory effect on tumor growth.

[0066] Summary: We invented a mutant of the SFTA3 gene, tSFTA3. If it is empty into the pLVX-puro vector and transfected into lung cancer cells, it can significantly inhibit cell growth in vitro, enhance sensitivity to targeted drugs, and inhibit tumor growth in animal experiments.

[0067] It will be clear to those skilled in the art that various modifications to the above embodiments may be made without departing from the overall spirit and concept of the present invention. All of these modifications fall within the scope of protection of the present invention. The protection scheme of the present invention shall be subject to the claims attached to the present invention.

Claims

1. Application of tSFTA3 in the preparation of drugs for preventing and treating lung adenocarcinoma; wherein: The base sequence of the tSFTA3 is shown in SEQ ID NO:

1.

2. Use of tSFTA3 according to claim 1 in the preparation of a drug for preventing and treating lung adenocarcinoma; wherein, The upstream added sequence of tSFTA3 is the Kozak sequence: GCCACC.

3. Use of tSFTA3 according to claim 1 in the preparation of a drug for preventing and treating lung adenocarcinoma; wherein, The downstream added sequence of tSFTA3 is the V5 tag of SEQ ID NO:

2.

4. Use of tSFTA3 according to claim 1 in the preparation of a drug for preventing and treating lung adenocarcinoma; wherein, The tSFTA3 is loaded into a lentiviral expression vector.

5. Use of tSFTA3 according to claim 4 in the preparation of a drug for preventing and treating lung adenocarcinoma; wherein, The tSFTA3 is used in the preparation of drugs for preventing and treating lung adenocarcinoma in the form of a truncated mutant expression vector pLVX-puro-tSFTA3. The truncated mutant expression vector pLVX-puro-tSFTA3 is obtained by using a lentiviral expression vector pLVX-Puro as a vector and inserting tSFTA3.

6. Use of tSFTA3 to inhibit proliferation of A549 cells or H358 cells for non-diagnostic therapeutic purposes in vitro; wherein, The base sequence of the tSFTA3 is shown in SEQ ID NO:

1.

7. Use of tSFTA3 in combination with at least one of trametinib, dabrafenib, and sotolacib in the preparation of a product for the prevention and treatment of lung adenocarcinoma; wherein: The base sequence of the tSFTA3 is shown in SEQ ID NO:1.